LETTERS

Remitting distal lower extremity swelling with pitting oedema in acute sarcoidosis

Remitting distal extremity swelling with pitting oedema is a clinical manifestation that may be observed in different rheumatic conditions such as RSPE syndrome, polyarthritis rheumaitca, late onset undifferentiated spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, and more rarely in other rheumatic disease. In RSPE the swelling with pitting oedema predominantly involves the upper extremities symmetrically. This clinical finding may occur unilaterally in polymyalgia rheumatica and upper and lower limbs may be equally affected, whereas in seronegative spondyloarthropathies it has been described more frequently in lower extremities with asymmetric involvement.

The oedema is characterised by a rapid response to small doses of corticosteroids. The pathogenesis of swelling with pitting oedema has not been completely defined, but the distribution along the tenosynovial membranes suggests that it probably results from tenosynovitis.

Sarcoidosis is a systemic granulomatous disease that is associated with rheumatic manifestations in 6% to 39% of patients. The most common form of arthritis occurs acutely, involves preferentially the ankles, and is often the initial feature of sarcoidosis. Frequently, erythema nodosum and bilateral hilar adenopathy are associated with arthritis (Lofgren’s syndrome). Erythema nodosum may also be absent.

Periarticular oedema and tenosynovitis accompanying arthritis have been emphasised in some reports. However, remitting distal lower extremity swelling with pitting oedema of the dorsi of the feet in patients with acute sarcoidosis has not been mentioned in previous reports.

We describe five patients with acute sarcoidosis who presented as first manifestation of the disease an impressive distal lower extremity swelling with pitting oedema of the dorsi of both feet. We made a retrospective review of all patients with acute sarcoidosis seen in two Italian Divisions of Internal Medicine (Prato and Reggio Emilia Hospitals) over a two year period. The diagnosis and presenting clinical features were assessed by clinical examination and review of the patient’s chart.

Remitting distal extremity swelling with pitting oedema was the presenting manifestation in five (29%) of 17 consecutive patients with acute sarcoidosis seen between January 1995 and December 1996. Table 1 summarises the demographic and clinical characteristics of the five patients. All patients presented with pain and swelling of both ankles and feet.

The swelling and pitting oedema were most prominent over the dorsi of both feet and ankles, malleolar and perimalleolar areas were also involved (fig 1). In perimalleolar areas the oedema followed the distribution of tibialis and peroneal tendons. It is possible that pitting oedema in our series may have been present in some other cases, but less pronounced and not considered by the examiner.

Swelling and oedema completely resolved after a few days of corticosteroid treatment.

To investigate the structures responsible for the swelling and oedema we examined three patients by magnetic resonance imaging.

Figure 1 Patient 2. Soft tissue swelling of malleolar and perimalleolar areas with pitting oedema of the dorsi of the right foot. The distribution of the oedema follows the course of peroneal, tibialis, and extensor tendons of the foot.

Figure 2 Patient 4. Right ankle axial magnetic resonance imaging (SE T2 weighted): pronounced tenosynovitis of posterior tibial tendon (arrow). Subcutaneous oedema and mild joint synovitis with scanty intrarticular fluid may be observed.

Table 1 Demographic, clinical, and magnetic resonance imaging features of the five patients with acute sarcoidosis

<table>
<thead>
<tr>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex/age at disease onset (y)</td>
<td>M/32</td>
<td>F/48</td>
<td>M/31</td>
<td>F/28</td>
</tr>
<tr>
<td>Pitting oedema of the dorsum of the foot</td>
<td>present</td>
<td>present</td>
<td>present</td>
<td>present</td>
</tr>
<tr>
<td>Systemic symptoms</td>
<td>low grade fever, fatigue present</td>
<td>low grade fever</td>
<td>low grade fever, fatigue</td>
<td>low grade fever, fatigue</td>
</tr>
<tr>
<td>Erythema nodosum</td>
<td>absent</td>
<td>present</td>
<td>absent</td>
<td>present</td>
</tr>
<tr>
<td>ESR/CRP*</td>
<td>42/35</td>
<td>65/52</td>
<td>76/56</td>
<td>61/45</td>
</tr>
<tr>
<td>SACE concentration†</td>
<td>58</td>
<td>65</td>
<td>70</td>
<td>57</td>
</tr>
<tr>
<td>Bilateral hilar adenopathy (x rays)</td>
<td>present</td>
<td>present</td>
<td>present</td>
<td>present</td>
</tr>
<tr>
<td>Gallium scan</td>
<td>increased</td>
<td>not performed</td>
<td>not performed</td>
<td>not performed</td>
</tr>
<tr>
<td>Bronchoalveolar lavage</td>
<td>not performed</td>
<td>not performed</td>
<td>CD4+ lymphocytic alveolitis</td>
<td>CD4+ lymphocytic alveolitis</td>
</tr>
<tr>
<td>Transbronchial biopsy</td>
<td>not performed</td>
<td>not performed</td>
<td>severe granulomas</td>
<td>non-caseating granulomas</td>
</tr>
<tr>
<td>Foot and ankle MRI findings</td>
<td>mild joint synovitis, severe tenosynovitis of all extensor tendons</td>
<td>mild joint synovitis, severe tenosynovitis of all extensor tendons</td>
<td>mild joint synovitis, severe tenosynovitis of all extensor tendons</td>
<td>mild joint synovitis, severe tenosynovitis of all extensor tendons</td>
</tr>
</tbody>
</table>

* ESR = erythrocyte sedimentation rate (mm 1st hour), CRP = C reactive protein (normal value: < 5 mg/l); † SACE = serum angiotensin converting enzyme (normal value: 18–55 U/l).
Further evidence that low androgen values are a cause of rheumatoid arthritis: the response of rheumatoid arthritis to seriously stressful life events

It is well established that androgen concentrations are low in patients with rheumatoid arthritis (RA). There are three possibilities: (1) Low androgen values are a consequence of RA. (2) Low androgen values are a consequence of its treatment. (3) Low androgen values are a partial cause of RA.

Undoubtedly the facts are complex, but in what I take to be an excess of methodological correctness, Masi et al write: "The available evidence reviewed does not allow definitive response to the question of a primary versus secondary role of sex hormone perturbations in RA. I shall treat the three above possibilities in turn to reject the difference in contrast with Masi et al's a definitive response is possible.

(1) Low androgen concentrations in men are a consequence of many forms of illness including severe inflammatory disease, so it may be accepted that this is one cause of the low androgen values.

(2) Acute and chronic administration of exogenous glucocorticosteroids can lower testosterone and DHA (See Masi et al for reference). So this may be another cause of low androgens in patients in treatment.

(3) However there are very substantial grounds for suspecting that low androgens are a partial cause of RA too: (a) RA is more common in women than in men. (b) RA is associated with HLA B 15, which in turn is associated with low androgen values in women. Hence the suggestion that low testosterone is a genetically determined precursor, rather than a consequence of RA or its treatment. A similar argument may be deployed in regard to HLA DR 4 in women (c) RA abates in about 75% of cases during pregnancy. (See Masi et al for reference). Some weeks to months after delivery, the disease flares in more than 90% of these patients. During pregnancy, increasing quantities of androgens are produced by the corpus luteum, placenta, and fetal male gonads. According to this hypothesis, amelioration during pregnancy is caused by these hormones, and the subsequent relapse is caused by their withdrawal. (d) Controls have been shown to have higher testosterone concentrations than patients in case-control studies: these data are consistent with any of the three propositions above. But the point has been established in a longitudinal study too: women who later developed RA had significantly lower DHAS values than controls who did not later develop the disease. Such a finding, if it were confirmed would not be adequately explained by propositions 1 or 2. (c) Direct administration of testosterone into male and postmenopausal female patients has resulted in improvement. It would be interesting to see the effect of such treatment for premenopausal women.

In the attempt to further inculpare low testosterone values in the aetiology of RA, I wish to draw attention to further confirmatory evidence in the shape of two dramatic cases reported in the behavioural literature.

The first is that of an elderly female RA patient who survived a lightning strike during a thunderstorm. Her walking stick was allegedly charred and her symptoms almost totally abated, though they subsequently returned before her death. I can vouch for the authenticity of the substance of this story: the lady was my aunt and she certainly suffered a shock (though not necessarily an electrical one). She regarded her experience as the occasion of a miracle.

The second case was that of a 53 year old female RA patient who suffered the unexpected deaths of her sisters and husband. Her disease went into temporary remission within a week of the deaths.

Stress in both sexes leads to increased pituitary secretion of adrenocorticotropic hormone. In men this causes this gonadal steroid production. In women, adrenocorticotropic hormone activation of the adrenal cortex is suspected of leading to increased overall androgens. In women, the main source of androgens is the adrenal gland whereas in men it is the gonads. So I suggest that these two cases illustrate the beneficial effects of androgens on RA.

There are two ways in which this could be tested: (1) If I am right, such severely stressful life events would have an exacerbating effect on male patients. (2) If I am right, the beneficial effects of pregnancy should be more evident in women carrying male fetuses (because male fetuses secrete more androgens than female fetuses).
Remitting distal lower extremity swelling with pitting oedema in acute sarcoidosis

FABRIZIO CANTINI, LAURA NICCOLI, IGNAZIO OLIVIERI, LIBERO BAROZZI, PIETRO PAVLICA, ALESSANDRO BOZZA, PIER LUIGI MACCHIONI, ANGELA PADULA and CARLO SALVARANI

Ann Rheum Dis 1997 56: 565-566
doi: 10.1136/ard.56.9.565

Updated information and services can be found at:
http://ard.bmj.com/content/56/9/565

These include:

References
This article cites 10 articles, 0 of which you can access for free at:
http://ard.bmj.com/content/56/9/565#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/